Abstract | PURPOSE: To evaluate the feasibility of 1-(4-amino- 2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride ( ACNU) of pre-treated procarbazine for elderly patients with newly diagnosed glioblastomas. PATIENTS AND METHODS: From January 2004 to March 2005, 7 patients with glioblastoma were enrolled. After maximal surgical resection, patients were treated with two to four cycles of procarbazine (100 mg/m(2) for day 1 to 5), ACNU (80 mg/m(2)/day(1) for day 5), cepharantine (70 mg for day 5 and 12) and vincristine (1.4 mg/m(2) for day 5 and 12). RESULTS: Significant toxicities of this regimen, including infectious toxicities, are described. Among the 7 patients enrolled, there were 6 patients were died, and one was still alive with disease at 13 months. The 6-month progression-free survival and 1-year overall survival are 29% (95% CI, 16% to 73%) and 29% (95% CI, 16% to 73%), respectively. CONCLUSION:
|
Authors | Mizuhiko Terasaki, Toshi Abe, Naohisa Miyagi, Etsuyo Ogo, Minoru Shigemori |
Journal | Journal of neuro-oncology
(J Neurooncol)
Vol. 81
Issue 3
Pg. 265-9
(Feb 2007)
ISSN: 0167-594X [Print] United States |
PMID | 16937011
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Alkaloids
- Benzylisoquinolines
- Nimustine
- Procarbazine
- Vincristine
- cepharanthine
|
Topics |
- Aged
- Alkaloids
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Benzylisoquinolines
- Brain Neoplasms
(drug therapy, mortality)
- Disease-Free Survival
- Feasibility Studies
- Female
- Glioblastoma
(drug therapy, mortality)
- Humans
- Male
- Middle Aged
- Neutropenia
(chemically induced)
- Nimustine
(therapeutic use)
- Procarbazine
(therapeutic use)
- Survival Analysis
- Treatment Outcome
- Vincristine
(therapeutic use)
|